Menu
← Oncology Approval Tracker
FDA DECISION ·
Tibsovo + azacitidine
ivosidenib plus azacitidine · Servier
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with newly diagnosed AML and a susceptible IDH1 mutation identified by an FDA-approved test, age 75 or older or with comorbidities precluding intensive induction chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The combination introduces an IDH1-directed option for newly diagnosed patients unsuited to intensive induction.
What research teams should watch
Confirm IDH1 testing and the basis for induction ineligibility. Plan escalation for differentiation syndrome.
PRIMARY RECORDS